Reply to: Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein

Reader response: Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes

(2020) Nizar Chahin et al.   NEUROLOGY

Monoclonal gammopathies of clinical significance

(2020) Angela Dispenzieri   Hematology-American Society of Hematology Education Program

Sporadic late-onset nemaline myopathy

(2019) Elie Naddaf et al.   NEUROLOGY

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications

(2018) Jean-Paul Fermand et al.   BLOOD

Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort

(2018) Mauro Monforte et al.   JOURNAL OF NEUROLOGY

Monoclonal gammopathy with both nemaline myopathy and amyloid myopathy

(2017) Min Wang et al.   NEUROMUSCULAR DISORDERS

Sporadic late-onset nemaline myopathy with MGUS: Long-term follow-up after melphalan and SCT

(2014) N. C. Voermans et al.   NEUROLOGY

Sporadic late onset nemaline myopathy responsive to IVIg and immunotherapy

(2009) Margherita Milone et al.   MUSCLE & NERVE